Compare Amgen, Inc. (AMGN) vs Nike Inc (NKE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Nike Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Nike Inc trades at $44.43 (market cap $65.71B). The key difference: Amgen, Inc. is far larger — about 3× Nike Inc's market cap, and Nike Inc pays the higher dividend (3.7%). Which is the better fit depends on your goals.
| AMGN | NKE | |
|---|---|---|
Market Cap | $196.12B | $65.71B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $79.24 |
52-Week Low | $271.18 | $40.75 |
Enterprise Value | $241.41B | $67.71B |
Dividend Yield | 2.77% | 3.7% |
Volume | — | 8,887,180 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Nike (NKE) trades at $44.37, up 3.72% today, with a bearish technical signal but strong profitability metrics including a 22.14% ROE. Recent earnings have consistently beaten estimates, though revenue declined to $46.31B in 2025. The stock faces headwinds from inventory challenges and softer demand in key markets like China, yet maintains a dominant brand position and analyst consensus price target of $50.67.
The outlook hinges on Nike's turnaround strategy stabilizing earnings amid competitive pressures. Investment opportunity lies in brand strength and digital growth, but risks include margin compression and macroeconomic sensitivity. Wall Street sentiment is mixed with 48.57% buy ratings, reflecting cautious optimism for execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →
